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Abstract 
Low concentrations of the calmodulin antagonist W-7 (l-10@) enhanced the respiratory burst (RB) of human polymorphonuclear leukocytes 
(PMN) stimulated by N-formyl-methionyl-leucyl-phenylalanine, whereas high drug concentrations (above 20pM) depressed it. The maximal increase 
obtained with 5-10~M W-7 affected both initial rate (50%) and total superoxide anion production (150%). W-7 also primed both parameters of the 
RB mediated by platelet-activating factor, although higher drug con~ntrations were required (15-50pM). By contrast, W-7 depressed the RB induced 
by the calcium ionophore A23187 and by a protein kinase C activator, phorbol my&ate acetate, with an IC,, of approximately 20 and 8 PM, 
respectively. These data show the enhancing effect of W-7 on chemoattractant-mediated RB and suggest hat RB priming may involve calmodulin- 
dependent regulation of chemoattractant-mediated early signalling events. 
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Stimulation of polymorphonuclear leucocytes (PMN) 
by soluble and particulate stimuli triggers rapid and mas- 
sive production of superoxide anions, the so-called ‘res- 
piratory burst’, which plays an important role in the 
killing of bacteria and in host tissue damage [l-33. Stim- 
ulation of the PMN respiratory burst by chemoattrac- 
tants such as formyl peptides (fMLP), platelet-activating 
factor (Paf), leukotriene B4 or C5a is partly dependent 
on mobilization of intracellular calcium [46]. Non-stim- 
ulatory concentrations of agonists [7,8] and some phar- 
macological agents [9,10] accelerate and potentiate the 
PMN respiratory burst induced by a second stimulus. 
This phenomenon, termed ‘priming’, may account for 
exaggerated physiolo~cal PMN responses. Priming and 
stimulation of PMN has been proposed to occur through 
different mechanisms [ 111. 
Cahnodulin, a ubiquitous low-molecular-weight pro- 
tein, regulates the calcium-dependent activity of various 
enzymes [12,13]. The possibility that calmodulin regu- 
lates PMN functions is supported by reports indicating 
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tration that reduces control values by 50%; W-7, N-(6-a~nohexyl)-5- 
chloro-1-naphtalene~lphonamjde. 
its presence in PMN [14] and by alterations of PMN 
functions by pha~acolo~cal inhibitors. Among these, 
W-7, a specific calmodulin antagonist [15], has been 
shown to depress the fMLP-mediated respiratory burst, 
aggregation, exocytosis, and directed locomotion [ 16 
193, indicating a positive role for calmodulin in these 
PMN functions. In this report, we describe a novel prop- 
erty of W-7: its ability to sharply enhance stimulation of 
the PMN respiratory burst by two chemoattractants, 
fMLP and Paf, a finding which suggests a role for calm- 
odulin in RB priming. 
2. Materials and methods 
2.1. Reagents 
W-7 was from Calbiochem (Meudon, France), Dextran T-500 was 
from Pharmacia (Uppsala, Sweden) and other reagents were from 
Sigma Co (St. Louis, MO). 
2.2. PMN preparation 
One volume of human venous blood, heparinized at 10 units/ml, was 
incubated with one volume of 2% Dextran in saline for 40 min. The 
supematant was centrifuged on a cushion of a mixture of 14.1% 
Nycodenz (~-~-b~2,3-~hy~ox~ropyl)-5-[~(2,3~hydrox~ropyl) 
acet~ido~-2,4,~triodo-isophtal~ide), 0.44% NaCl, and 5 mM 
Tricine/NaOH, pH 7.0 (J.N. Prep from J. Bio Sa, Les Ullis, France). 
The purified PMN (97%) were subjected to hypotonic lysis, washed and 
resuspended in Hank’s balanced salt solution HBSS) at pH 7.4. 
2.3. PA4N respiratory burst 
The production of superoxide anion was continuously recorded by 
monitoring the superoxide dismutase-inhibitable r duction of cyto- 
chrome c [20], using a WIKON 860 s~trophotometer equipped with 
a thermostatted (37°C) cuvette holder and a magnetic stirrer. Suspen- 
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sions of 2 x lo6 PMN in 2 ml HBSS were incubated in the absence 
(control) or presence of W-7 before stimulation, under conditions de- 
scribed in the figure legends. The final concentration of drug solvent 
(DMSO) did not exceed 0.1% and had no discernable ffect on RB. The 
initial rate and total production of superoxide anion are expressed as 
percentages of control values. 
2.4. Statistical analysis 
Statistically significant differences between the results of experiments 
performed in the presence and absence W-7 were determined using 
Student’s paired t-tests with a threshold of P < 0.05. 
3. Results and discussion 
Fig. 1 shows compares the effects of W-7 on the initial 
rate and total production of superoxide induced by 100 
nM fMLP. Treatment of PMN for 5 min with W-7 con- 
centrations from 1 to 15 ,uM, while having no stimula- 
tory effect, strongly enhanced (P < 0.01) the total pro- 
duction of superoxide, with a maximal effect reaching 
approximately 150% of control values. This potentiation 
also affected the initial rate, but to a lesser extent. These 
data suggest that biochemical modifications resulting 
from W-7 action may affect signalling events that control 
both the initiation and termination processes of the res- 
piratory burst. W-7 concentrations above 20 ,uM simi- 
larly inhibited both parameters of the respiratory burst, 
in agreement with earlier reports [16-181. 
We have previously shown that a potent PKC inhibi- 
tor, staurosporine, also primes these parameters of the 
PMN respiratory burst mediated by fMLP and Paf [lo]. 
However, this priming effect required at least 10 min of 
PMN pretreatment with the drug [21]. Unlike stauro- 
sporine, the enhancing effects of W-7 were observed after 
both short and long treatment periods (l-40 min) before 
, 
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Fig. 1. Effect of W-7 on the fMLP-mediated PMN respiratory burst. 
PMN were treated at 37°C in the absence (control) or presence of 
indicated W-7 concentrations for 5 min before stimulation with 0.1 ,uM 
WLP. The initial rate and total amount of superoxide anion produc- 
tion are expressed as % of control values (3.7 f 0.2 nmoVmin and 
5.3 It 0.4 nmoY106 cells, respectively). 
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Fig. 2. Effect of the duration of cell treatment on the fMLP-mediated 
respiratory burst. PMN were treated in the absence (control) or pres- 
ence of 10 PM W-7 for the indicated periods before stimulation with 
0.1 ,uM WLP. Initial rate and total production of superoxide anion are 
the mean of two experiments and are expressed as % of respective 
controls. 
PMN stimulation, indicating that these two drugs may 
prime the respiratory burst through different mecha- 
nisms. 
To gain insight into possible sites of action of W-7, its 
effects were tested on the PMN respiratory burst medi- 
ated by three other stimuli known to operate through 
different pathways: platelet-activating factor (Paf), a 
chemoattractant which stimulates PMN through mem- 
brane receptor stimulation; PMA, a direct PKC activa- 
tor [22], and the calcium ionophore A23187. The results 
in Fig. 3 show that W-7 also primed both parameters of 
the PMN respiratory burst mediated by 1 PM Paf. How- 
ever, the drug concentrations required were higher than 
those used with fMLP (Fig. 1). When PMN were stimu- 
lated with 160 nM PMA for 10 min, W-7 depressed 
respiratory burst parameters with an I& of approxi- 
mately 8 PM (Fig. 4). W-7 also inhibited the respiratory 
burst mediated by the calcium ionophore A23187 with 
an IC,, of approximately 30 PM (Fig. 5). 
The main observation described above is that low con- 
centrations of W-7 strongly enhanced the production of 
superoxide by PMN stimulated by two chemoattrac- 
trants, whereas high drug concentrations were inhib- 
itory. These data partly contrast with previous findings 
showing only inhibitory effects of W-7 on fMLP-medi- 
ated RB [ 16,181. Although a small potentiating effect on 
oxygen consumption of rabbit PMN has been found to 
OCCUI occasionally [16], the major effects of W-7 are 
considered to be inhibitory, as the drug also depresses 
other PMN functions mediated by NLP such as aggre- 
gation, exocytosis [ 16,171 and directed locomotion [20]. 
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Fig. 3. Effect of W-7 on the Paf-mediated PMN respiratory burst. PMN 
were treated at 37°C in the absence (control) or presence of indicated 
W-7 concentrations for 5 min before stimulation with 1 ,uM Paf. Initial 
rate and total production of superoxide are expressed as % of control 
values (2 3 + 0.1 mnol/min and 2.3 + 0.2 nmol/l@ PMN, respectively). 
The reason for this descrepancy between W-7 effects in 
our study and others is difficult to explain. However, one 
possibility is the use of cells from different sources; for 
example, elicited rabbit PMN [16] which have been re- 
ported to be already primed relative to blood PMN [23]. 
The ability of W-7 to modulate chemoattractant-medi- 
ated RB as a function of the drug concentration suggests 
that the cellular modifications induced by W-7 affect 
distinct calmodulin-dependent events that may have a 
different role in the mechanism of RB stimulation. The 
comparison of W-7 effects on the respiratory burst medi- 
ated by pharmacological stimuli such as A23187 and 
PMA is informative, given the mechanism by which 
these agents induced cellular responses. Indeed, W-7 
only inhibited the PMN respiratory burst induced by the 
latter stimulus, whatever the drug concentration (Figs. 
4 and 5), in agreement with other reports [20,24]. W-7 
also depresses the PMN responses mediated by ara- 
chidonic acid [16], a free fatty acid that bypasses the 
plasma membrane receptor step and acts at a step that 
precedes calcium mobilization [25]. These data indicate 
that the biochemical alterations mediated by the drug 
may occur at a step downstream of calcium mobilization 
and PKC activation [16]. Supporting this possibility is 
the recent observation that W-7 inhibits phospholipase 
D activation in fMLP-stimulated PMN, a finding that 
was interpreted as being due to inhibition of calmodulin 
kinase [26]. In fMLP-stimulated PMN, the PLD path- 
way provides the bulk of phosphatidic acid and diglyc- 
eride production [27], and has been linked to respiratory 
burst stimulation [28,29]. Inhibition of PLD activation 
by W-7 may thus contribute to the depression of che- 
moattractant-mediated respiratory burst by W-7 [ 17,181 
(Figs. 1 and 3). 
The priming of fMLP-mediated PMN respiratory 
burst by W-7 occurs at a drug concentration close to its 
binding constant to purified calmodulin, i.e. approxi- 
mately 11 ,uM [30], which indicates that W-7 may exert 
its effects through association with calmodulin. How- 
ever, with Paf, higher drug concentrations were required 
for priming (Fig. 3). This difference reinforces the possi- 
bility that the two chemoattractants induce PMN activa- 
tion through different mechanisms [31]. The fact that 
W-7 selectively enhanced fMLP and Paf-mediated respi- 
ratory burst suggests that the major modifications that 
lead to RB priming may take place between receptor 
stimulation and activation of transductional effecters 
that generate second messengers. This is supported by 
the observation that W-7 induces activation of phospho- 
lipase D in cultured LA-N-2 cells [32]. We have also 
found that W-7 induces activation of PLD in human 
PMN (results not shown), as evidenced by production of 
phosphatidylethanol[33]. Whether this activation occurs 
through a modification of regulatory components or di- 
rect nonspecific interaction of W-7 with PLD remains to 
be determined. Supporting the former possibility is the 
observation that calmodulin induces activation of 
adenylate cyclase [34] through binding to br subunits of 
Gi [34,35]. Inhibition of calmodulin by W-7 may thus 
prime the RB through an attenuation of the cyclic AMP- 
mediated down-regulation of PLD activation, as re- 
ported in fMLP-stimulated PMN [36]. Alternatively, W- 
7 may induce activation of G proteins that regulate PLD 
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Fig. 4. Effect of W-7 on the PMA-mediated PMN respiratory burst. 
PMNB were treated at 37°C in the absence (control) or presence of 
indicated W-7 concentrations for 5 min before stimulation with 160 nM 
PMA for 10 min. Initial rate and total amount of superoxide are 
expressed as % of control values (4.5 f 0.8 mnol/min and 16.9 f 2 nmol 
per lo6 cells, respectively). 
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Fig. 5. Effect of W-7 on A23187-mediated PMN respiratory burst. 
PMN were treated at 37°C in the absence (control) or presence of 
indicated W-7 concentrations for 5 min before stimulation with 10 pM 
A23 187. Initial rate and total amount of superoxide anion are expressed 
as % of control values (1.9 f 0.2 nmol/min and 5.7 + 0.5 nmol per lo6 
cells, respectively). 
activation. Activation of Gi has been proposed as a 
mechanism by which a potent PKC inhibitor, stauro- 
sporine, induces activation of PLD in rabbit PMN [37]. 
In human PMN, staurosporine also stimulates PLD acti- 
vation and this may contribute to its priming effect on 
fMLP- and Paf-mediated respiratory burst [lo]. While 
the biochemical modifications involved in enhancing 
PLD activation and the respiratory burst remains to be 
identified, our results suggest that drugs known to antag- 
onize the effects of calmodulin, i.e. some local anesthet- 
ics, chlorpromazine and trifluoroperazine, may poten- 
tially enhance chemoattractant-mediated physiological 
PMN functions and therefore their destructive proper- 
ties. 
In summary, low concentrations of the calmodulin 
antagonist W-7 were found to enhance the respiratory 
burst of human PMN stimulated by two chemoattrac- 
tants, fMLP and Paf, wheras higher drug concentrations 
were inhibitory. This priming effect of W-7 may involve 
regulation of early signalling events mediated by che- 
moattractant receptor stimulation. 
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